Literature DB >> 25340498

Beijing lineage of MDR Mycobacterium tuberculosis in Bulgaria, 2007-2011.

Stefan Panaiotov, Elizabeta Bachiyska, Stanislava Yordanova, Yuliana Atanasova, Nadia Brankova, Viktoria Levterova, Sarah Sengstake, Richard Anthony, Indra Bergval, Christophe Sola, Todor Kantardjiev.   

Abstract

To assess the spread of the Mycobacterium tuberculosis Beijing genotype among patients with multidrug-resistant and extensively resistant tuberculosis in Bulgaria, we genotyped 188 (72%) of 261 microbiologically confirmed resistant isolates obtained during 2007-2011. The estimated prevalence of the Beijing genotype among these patients was 3.2%.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25340498      PMCID: PMC4214304          DOI: 10.3201/eid2011.140468

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


In 1995, the Beijing genotypic family was identified in Beijing, China, where it accounted for at least 86% of Mycobacterium tuberculosis isolates (). Genotyping of 2,092 multidrug resistant (MDR) and extensively drug-resistant (XDR) strains, isolated in 24 European countries during 2003–2011, indicated that 470 (22.5%) strains belonged to the Beijing lineage, many of which originated from eastern European countries (). Strains of this genotypic family account for at least 13% of M. tuberculosis strains worldwide, and the percentage seems to be increasing (,). Bulgaria is 1 of 27 countries that the World Health Organization describes as having a high burden of MDR tuberculosis (TB). TB case notification rates in Bulgaria were 39.6 cases/100,000 population (3,038 cases) in 2007, 41.2 cases/100,000 population (3,150 cases) in 2008, 38.3 cases/100,000 population (2,910 cases) in 2009, 35 cases/100,000 population (2,649 cases) in 2010, and 32.1 cases/100,000 population (2,407 cases) in 2011. During this same period, the MDR/XDR TB notification rate was 7.5% (76 cases) in 2007, 3.3% (31 cases) in 2008, 5.1% (43 cases) in 2009, 5.8% (56 cases) in 2010, and 7.5% (55 cases) in 2011 (). In a nationwide study of 197 drug-susceptible isolates obtained during 2003–2004, no isolates of the Beijing genotype were identified in Bulgaria (). A subsequent study also did not identify the Beijing genotype among 133 drug-resistant and drug-susceptible M. tuberculosis isolates obtained during 2004–2006 (). Since then, Beijing strains of M. tuberculosis have been identified during routine screening of MDR/XDR TB isolates in Bulgaria. In this study, after receiving ethics approval, we assessed the spread of the M. tuberculosis Beijing genotype among patients with MDR and XDR TB in Bulgaria.

The Study

In Bulgaria during 2007–2011, a total of 188 MDR/XDR M. tuberculosis isolates were characterized by drug-susceptibility testing and spoligotyping (31 in 2007, 31 in 2008, 39 in 2009, 47 in 2010, and 40 in 2011) and represent 72% of the 261 MDR/XDR M. tuberculosis isolates identified during that period. The MDR/XDR strains were isolated from sputum of 181 (96.2%) patients, gastric lavage fluid from 3 (1.5%), bronchoalveolar lavage fluid from 2 (1%), pleural fluid from 1 (0.5%), and fistula swab sample from 1 (0.5%). The first MDR/XDR M. tuberculosis strain isolated per patient was analyzed for this study. Drug susceptibility of these strains was confirmed by the National Reference TB Laboratory, which used liquid culture at concentrations of 0.1 μg/mL for isoniazid, 1 μg/mL for rifampin, 5 μg/mL for ethambutol, 1 μg/mL for streptomycin, 2.5 μg/mL for capreomycin, 1 μg/mL for amikacin, 5 μg/mL for kanamycin, and 2 μg/mL for ofloxacin. Of the MDR/XDR strains, 77 (41%) were resistant to all first-line anti-TB drugs, 51 (27%) were resistant to isoniazid and rifampin; 38 (20%) to isoniazid, rifampin, and streptomycin; and 22 (12%) to isoniazid, rifampin, and ethambutol. Second-line drug-susceptibility testing was performed for 174 (81%) of the MDR strains. Of these, 140 (80%) were sensitive to all second-line anti-TB drugs and 20 (12%) were resistant to ofloxacin. Five percent (n = 9) of XDR strains had combined resistance to ofloxacin, amikacin, kanamycin, and capreomycin. To detect and genotype the Beijing strains, we used a spoligotyping kit (Isogen Bioscience BV, Maarssen, the Netherlands), and we performed single-nucleotide polymorphism typing by bead-based multiplex ligation-dependent probe amplification (MLPA) (,). We also screened for the presence of the Beijing genotype in 117 drug-sensitive strains collected from across the country in 2011, representing a convenience sample of ≈10%. Both methods identified 1 drug-sensitive M. tuberculosis strain of the Beijing genotype (BG_112_11, Table 1). The MLPA test assigned this isolate to the Beijing K1 sublineage ().
Table 1

Phenotypic characteristics of the Mycobacterium tuberculosis Beijing genotype strains identified in Bulgaria, 2007–2011*

Strain Patient 
originPatient age ,y/sexCase statusDrug
susceptibilityFirst-line drugs
Second-line drugs
STRINHRIFEMBOFLAMKKANCAP
BG_07_09Dobrich35/MPTMDRRRRRSSSS
BG_35_09Sofia42/MNewMDRRRRRSSSS
BG_104_10Sofia25/FNewXDRRRRRRRRR
BG_85_10Varna32/MNewMDRRRRRSSSS
BG_95_10Varna59/MNewMDRRRRRSSSS
BG_112_11Sofia32/MNewSusceptibleSSSSNANANANA
BG_54_11Sofia48/MPTMDRRRRRSSSS

*AMK, amikacin; CAP, capreomycin; EMB, ethambutol; INH, isoniazid; KAN, kanamycin; NA, not applicable; OFL, ofloxacin; PT, previously treated; R, drug resistant; RIF, rifampin; S, drug sensitive; STR, streptomycin..

*AMK, amikacin; CAP, capreomycin; EMB, ethambutol; INH, isoniazid; KAN, kanamycin; NA, not applicable; OFL, ofloxacin; PT, previously treated; R, drug resistant; RIF, rifampin; S, drug sensitive; STR, streptomycin.. Among the 188 MDR/XDR strains collected during 2007–2011, a total of 6 isolates with the Beijing genotype were identified (prevalence 3.2%, 95% CI 0.7%–5.7%): 2 in 2009 (Beijing SA+/CHIN+/V+), 3 in 2010 (Beijing SA+/CHIN+/V+ and Beijing K1), and 1 in 2011 (Beijing SA+/CHIN+/V+). These 6 drug-resistant strains were isolated from 5 male and 1 female patients. Drug-susceptibility testing and molecular drug-resistance markers confirmed that 1 strain was XDR. A total of 4 strains were Spoligo International Type 1 (SIT1) and 2 strains were SIT265 (Tables 1 and 2). In the neighboring countries of Albania, Greece, Romania, and Turkey, no MDR M. tuberculosis Beijing strains were isolated or prevalence was 1%–3%, mostly of imported origin (–). The origins of the MDR/XDR strains and the drug-sensitive strain identified in Bulgaria are described below. Additional methods used and genotyping characteristics found are described in the Technical Appendix.
Table 2

Genotyping characteristics of the Mycobacterium tuberculosis Beijing genotype strains identified in Bulgaria, 2007–2011*

Strain Spoligotype patternSIT24 MIRU-VNTR†MLPA lineage type‡
BG_07_09⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬛⬛⬛⬛⬛⬛⬛⬛⬛1244233352634425153353823SA+/V+/ CHIN+
BG_35_09⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬛⬛⬛⬛⬛⬛⬛⬛⬛1244233352644425173343723SA+/V+/ CHIN+
BG_104_10⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬛⬛⬛⬛⬛⬛⬛⬛⬛1244233352644425153353823SA+/V+/ CHIN+
BG_85_10⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬛⬛⬜⬛⬛⬛⬛⬛⬛265244233352644425153353823K1
BG_95_10⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬛⬛⬜⬛⬛⬛⬛⬛⬛265244233352644425153353823K1
BG_112_11⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬛⬛⬛⬛⬛⬛⬛⬛⬛1NAK1
BG_54_11⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬜⬛⬛⬛⬛⬛⬛⬛⬛⬛1244233352634425153353823SA+/V+/ CHIN+

*MIRU, mycobacterial interspersed repetitive unit; NA, not applicable; SIT, Spoligo International Type second to SITVITWEB database classification; VNTR, variable number–tandem repeat.
†24 loci MIRU-VNTR order: 154, 424, 577, 580, 802, 960, 1644, 1955, 2059, 2163b, 2165, 2347, 2401, 2461, 2531, 2687, 2996, 3007, 3171, 3192, 3690, 4052, 4156, 4348.
‡SA+, South Africa; V+, Vietnam; CHIN+, China; K1, Uzbekistan (,).

*MIRU, mycobacterial interspersed repetitive unit; NA, not applicable; SIT, Spoligo International Type second to SITVITWEB database classification; VNTR, variable number–tandem repeat.
†24 loci MIRU-VNTR order: 154, 424, 577, 580, 802, 960, 1644, 1955, 2059, 2163b, 2165, 2347, 2401, 2461, 2531, 2687, 2996, 3007, 3171, 3192, 3690, 4052, 4156, 4348.
‡SA+, South Africa; V+, Vietnam; CHIN+, China; K1, Uzbekistan (,). The first XDR Beijing strain identified (BG_104_10) was from a patient who arrived in Bulgaria from Moldova in 2009 and in whom TB developed a few months later. Before coming to Bulgaria, the patient had had contact with a TB patient in Ukraine. The first M. tuberculosis isolate recovered from this Moldovan patient was confirmed as primary XDR M. tuberculosis. The patient received treatment with second-line TB drugs in 2010, underwent surgery, and in 2011 was considered cured. The 2 SIT265 Beijing genotype clinical isolates (BG–85-10 and BG–95–10) originated from 2 neighbors. One patient was an alcohol-dependent sailor in whom TB developed after a ship voyage. TB developed in his neighbor (who had diabetes) a few months later. M. tuberculosis transmission most likely occurred between them. The epidemiologic link was supported by identical drug-susceptibility testing results, MLPA, spoligotyping, and variable number–tandem repeat typing profiles with no similarities to other genotypes identified in Bulgaria. Most of the 50 SIT265 Beijing genotype strains, reported in the SITVITWEB database (http://www.pasteur-guadeloupe.fr:8081/SITVIT_ONLINE), originated from the United States, Russia, Israel, and Spain (). Both patients were receiving treatment as of 2012. The other 3 MDR Beijing isolates had different VNTR patterns but shared the same SIT1 spoligotype and the same MLPA lineage type (SA+/V+/CHIN+) (Table 2). Of these 3 patients, 2 lived in the capital city of Sofia (with strains BG_54_11 and BG_112_11) and the third (with strain BG_07_09) lived in Dobrich, in the northeastern part of the country. The patient was alcoholic, antisocial, and homeless and refused treatment. The MDR TB was diagnosed in 2007, but the strain was lost. In 2009, the patient was hospitalized, and Beijing genotype MDR M. tuberculosis was identified. The patient died that same year. Another Beijing strain was identified in 2009 from a patient who lived in Sofia (BG_35_09, Tables 1 and 2). The patient’s parents were from Armenia, where the prevalence of the Beijing genotype is no less than 41% () and prevalence of MDR TB in 2009 was 22.9% (). The patient had not been to Armenia, but the possibility of casual contact with migrating Armenians was not excluded. This patient died in 2010.

Conclusions

Among MDR/XDR M. tuberculosis isolates in Bulgaria, prevalence of the Beijing genotype is low. Not all detected cases of TB caused by the Beijing genotype were a result of human migration; MDR/XDR TB transmission within the country was also observed. The M. tuberculosis Beijing genotype strains are considered to be large drivers of international TB transmission and are associated with the emergence and spread of MDR/XDR TB (). This finding demands organization of wider surveillance in Bulgaria that includes monitoring genotypes of drug-susceptible and drug-resistant M. tuberculosis strains.

Technical Appendix

Additional methods used and genotyping characteristics found for the identified Mycobacterium tuberculosis Beijing strains isolated in Bulgaria during 2007–2011.
  11 in total

1.  SITVITWEB--a publicly available international multimarker database for studying Mycobacterium tuberculosis genetic diversity and molecular epidemiology.

Authors:  Christophe Demay; Benjamin Liens; Thomas Burguière; Véronique Hill; David Couvin; Julie Millet; Igor Mokrousov; Christophe Sola; Thierry Zozio; Nalin Rastogi
Journal:  Infect Genet Evol       Date:  2012-02-17       Impact factor: 3.342

2.  First insight into genetic diversity of the Mycobacterium tuberculosis complex in Albania obtained by multilocus variable-number tandem-repeat analysis and spoligotyping reveals the presence of beijing multidrug-resistant isolates.

Authors:  Silva Tafaj; Jian Zhang; Yolande Hauck; Christine Pourcel; Hasan Hafizi; Grigor Zoraqi; Christophe Sola
Journal:  J Clin Microbiol       Date:  2009-03-11       Impact factor: 5.948

3.  Molecular surveillance of multi- and extensively drug-resistant tuberculosis transmission in the European Union from 2003 to 2011.

Authors:  J L De Beer; C Kodmon; M J van der Werf; J van Ingen; D van Soolingen
Journal:  Euro Surveill       Date:  2014-03-20

4.  Prevalence of Beijing genotype Mycobacterium tuberculosis strains in Istanbul.

Authors:  O K Koksalan; Z Kilicaslan; G Zanlier; R Guzel; E Seber
Journal:  Int J Tuberc Lung Dis       Date:  2006-04       Impact factor: 2.373

5.  MIRU-VNTR typing of drug-resistant tuberculosis isolates in Greece.

Authors:  Nikoletta Rovina; Simona Karabela; Pantelis Constantoulakis; Vassiliki Michou; Konstantinos Konstantinou; Vassileios Sgountzos; Charis Roussos; Nikolaos Poulakis
Journal:  Ther Adv Respir Dis       Date:  2011-04-07       Impact factor: 4.031

6.  Predominance of a single genotype of Mycobacterium tuberculosis in countries of east Asia.

Authors:  D van Soolingen; L Qian; P E de Haas; J T Douglas; H Traore; F Portaels; H Z Qing; D Enkhsaikan; P Nymadawa; J D van Embden
Journal:  J Clin Microbiol       Date:  1995-12       Impact factor: 5.948

7.  Molecular characterization of Mycobacterium tuberculosis isolates from different regions of Bulgaria.

Authors:  Violeta Valcheva; Igor Mokrousov; Nalin Rastogi; Olga Narvskaya; Nadya Markova
Journal:  J Clin Microbiol       Date:  2008-01-16       Impact factor: 5.948

8.  Definition of the Beijing/W lineage of Mycobacterium tuberculosis on the basis of genetic markers.

Authors:  Kristin Kremer; Judith R Glynn; Troels Lillebaek; Stefan Niemann; Natalia E Kurepina; Barry N Kreiswirth; Pablo J Bifani; Dick van Soolingen
Journal:  J Clin Microbiol       Date:  2004-09       Impact factor: 5.948

9.  SNP/RD typing of Mycobacterium tuberculosis Beijing strains reveals local and worldwide disseminated clonal complexes.

Authors:  Anita C Schürch; Kristin Kremer; Amber C A Hendriks; Benthe Freyee; Christopher R E McEvoy; Reinout van Crevel; Martin J Boeree; Paul van Helden; Robin M Warren; Roland J Siezen; Dick van Soolingen
Journal:  PLoS One       Date:  2011-12-05       Impact factor: 3.240

10.  Combined species identification, genotyping, and drug resistance detection of Mycobacterium tuberculosis cultures by MLPA on a bead-based array.

Authors:  Indra Bergval; Sarah Sengstake; Nadia Brankova; Viktoria Levterova; Edgar Abadía; Nino Tadumaze; Nino Bablishvili; Maka Akhalaia; Kiki Tuin; Anja Schuitema; Stefan Panaiotov; Elizabeta Bachiyska; Todor Kantardjiev; Rina de Zwaan; Anita Schürch; Dick van Soolingen; Anja van 't Hoog; Frank Cobelens; Rusudan Aspindzelashvili; Christophe Sola; Paul Klatser; Richard Anthony
Journal:  PLoS One       Date:  2012-08-20       Impact factor: 3.240

View more
  3 in total

1.  Drug resistance characteristics and cluster analysis of M. tuberculosis in Chinese patients with multiple episodes of anti-tuberculosis treatment.

Authors:  Yi Hu; Qi Zhao; Jim Werngren; Sven Hoffner; Vinod K Diwan; Biao Xu
Journal:  BMC Infect Dis       Date:  2016-01-07       Impact factor: 3.090

2.  Tackling tuberculosis: Insights from an international TB Summit in London.

Authors:  Arundhati Maitra; Cynthia A Danquah; Francesca Scotti; Tracey K Howard; Tengku K Kamil; Sanjib Bhakta
Journal:  Virulence       Date:  2015-07-07       Impact factor: 5.882

3.  Biodiversity of Mycobacterium tuberculosis in Bulgaria Related to Human Migrations or Ecological Adaptation.

Authors:  Stefan Panaiotov; Dzheni Madzharov; Yordan Hodzhev
Journal:  Microorganisms       Date:  2022-01-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.